Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease
Background. Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis. Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia,...
Main Authors: | Ryan Jalleh, Gopal Basu, Richard Le Leu, Shilpanjali Jesudason |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Case Reports in Nephrology |
Online Access: | http://dx.doi.org/10.1155/2018/7384763 |
Similar Items
-
Denosumab and chronic kidney disease: Severe life-threatening hypocalcaemia
by: Pilar Monge Rafael, et al.
Published: (2018-01-01) -
Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
by: Florence Gunawan, et al.
Published: (2019-12-01) -
Severe hypocalcemia following denosumab injection in patient with chronic kidney disease
by: Pilar Monge Rafael, et al.
Published: (2016-07-01) -
Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis
by: Yuko Kanbayashi, et al.
Published: (2021-01-01) -
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01)